Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Chris L. Bellows"'
Autor:
Kiev S. Ly, Andrew Richard Hudson, Christine Hoffmaster, James T. Limberis, J. Guy Breitenbucher, Richard Barido, De Michael Chung, Yingzhuo Yan, Gary Anderson, Vincent J. Santora, Dany Gitnick, Dong Lee, Brett C. Bookser, Anne Danks, Robert E. Petroski, Graeme Freestone, Varsha Gupta, Clifford Cabebe, Andrew Morse, Michael R. Kennedy, Kristen Sebring, Zachary W. Yoder, Douglas Zook, Marco Peters, Chih-Kun Chai, Joel Renick, Jim Na, Theresa A. Almos, Shouzhen Xia, Ali Tabatabaei, John Nikpur, Samantha Sevidal, Stephine Chow, Mi Chen, Jillian Basinger, Chris L. Bellows, Lindsay Heger, David Neul, Jenny Wen, Brittany Masatsugu, Nicola J. Broadbent, Alan P. Kaplan, Chi Ching Mak
Publikováno v:
Bioorganicmedicinal chemistry letters. 30(14)
A strategy to conformationally restrain a series of GlyT1 inhibitors identified potent analogs that exhibited slowly interconverting rotational isomers. Further studies to address this concern led to a series of azetidine-based inhibitors. Compound 2
Autor:
David Neul, Andrew Morse, Joel Renick, Brittany Masatsugu, Chi Ching Mak, James T. Limberis, Dany Gitnick, Zachary W. Yoder, Michael R. Kennedy, Kiev S. Ly, Samantha Sevidal, Richard Barido, Robert E. Petroski, Graeme Freestone, Clifford Cabebe, Jillian Basinger, Vincent J. Santora, Christine Hoffmaster, Chris L. Bellows, Yingzhuo Yan, Mi Chen, De Michael Chung, John Nikpur, Kristen Sebring, Jenny Wen, Ali Tabatabaei, Brett C. Bookser, Theresa A. Almos, Andrew Richard Hudson, J. Guy Breitenbucher, Chih-Kun Chai, Dong Lee, Lindsay Crickard, Anne Danks, Varsha Gupta, Marco Peters, Alan P. Kaplan, Jim Na, Nicola J. Broadbent, Stephine Chow, Douglas Zook
Publikováno v:
Journal of Medicinal Chemistry. 61:6018-6033
We report here the identification and optimization of a novel series of potent GlyT1 inhibitors. A ligand design campaign that utilized known GlyT1 inhibitors as starting points led to the identification of a novel series of pyrrolo[3,4- c]pyrazoles
Publikováno v:
Bioanalysis. 4(17)
Background: Davalintide, an investigational therapeutic peptide for the treatment of obesity, is rapidly metabolized by enzymatic cleavage of its N-terminal lysine residue to produce an active des-Lys metabolite in vivo. While a sensitive ELISA assay